RxDoctor Payments Data

Megan Burgard

Psychiatric/Mental Health · Rapid City, SDNPI 1669949947

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 40 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by AbbVie at 39.5% of the total. Reporting peaked in 2023 at $456 and has fallen 57.0% since, to $196 in 2025.

$922in general payments, 2019–2025

Across 40 payments — averaging $23.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$364
  • Axsome Therapeutics, Inc.$182
  • Alkermes, Inc.$107
  • Otsuka America Pharmaceutical, Inc.$45
  • Supernus Pharmaceuticals, Inc.$44
  • Neurocrine Biosciences, Inc.$39
  • plus $142 from 6 others

What the payments were for

  • Food & beverage$922100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$922 in reported general payments places this provider in the 65th percentile of 77 psychiatric/mental health providers in South Dakota.

See all psychiatric/mental health providers in South Dakota

Medicare billing

Part B allowed, 2024
$30,143
Medicare patients
47
Services billed
203

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SpravatoEsketamine Hcl20$25,037
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine19$1,423
Bupropion XlBupropion Hcl33$1,261
Trazodone Hcl26$891
Duloxetine Hcl32$623
Quetiapine Fumarate21$480
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine15$344
Lithium Carbonate12$301
Aripiprazole16$280
Venlafaxine Hcl ErVenlafaxine Hcl15$258
Desvenlafaxine Succinate ErDesvenlafaxine Succinate11$214
Buspirone Hcl14$207
Fluoxetine Hcl21$187
Hydroxyzine Hcl13$187
Lorazepam31$185

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonSpravato$26$25,03720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 77 psychiatric/mental health providers in South Dakota.

Other psychiatric/mental health in Rapid City

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →